ADD THIS DRUG TO MY LIST

Select the drug indication to add to your list

ORFADIN ORAL SUSPENSION
Inborn errors of metabolism
Compare To Related Drugs
View/Edit/Compare Drugs In My List

Only 4 drugs may be compared at once

Drug Name:

ORFADIN ORAL SUSPENSION Rx

Generic Name and Formulations:
Nitisinone 4mg/mL; strawberry-flavored; contains glycerol 500mg/mL and sodium 0.7mg/mL.

Company:
Sobi, Inc.

Therapeutic Use:

Indications for ORFADIN ORAL SUSPENSION:

Treatment of hereditary tyrosinemia type 1 (HT-1) in combination with dietary restriction of tyrosine and phenylalanine.

Adults and Children:

Caps: take ≥1hr before or 2hrs after a meal. May open capsules and mix contents in water, formula, or apple sauce if difficulty swallowing caps or intolerant to oral susp. Initially 0.5mg/kg twice daily. Titrate individually as needed based on biochemical and/or clinical response. Monitor plasma and/or urine succinylacetone levels, liver function, and alpha-fetoprotein levels. Increase to 0.75mg/kg twice daily if succinylacetone is still detectable 1 month after treatment initiation; max 2mg/kg total daily dose may be needed. Maintenance: ≥5yrs with undetectable succinylacetone levels after a minimum of 4wks therapy on a stable dose: may give total daily dose once daily (eg, 1–2mg/kg once daily).

Warnings/Precautions:

Maintain dietary restriction of tyrosine and phenylalanine during therapy. Do not adjust dose to lower plasma tyrosine levels (maintain levels at <500μmol/L). Perform eye exams (including slit-lamp test) prior to starting therapy; re-evaluate and assess plasma tyrosine levels if ocular symptoms develop. Perform lab tests (including plasma tyrosine levels) if abrupt change in neurologic status occurs. Monitor platelets, WBC counts during therapy. Oral susp: glycerol content (>20mL as a single-dose) may increase risk of adverse effects (eg, headache, upset stomach, diarrhea). Elderly. Pregnancy. Nursing mothers.

Interactions:

May potentiate CYP2C9 substrates; monitor.

See Also:

ORFADIN

Pharmacological Class:

4-hydroxyphenylpyruvate dioxygenase inhibitor.

Adverse Reactions:

Elevated tyrosine levels, thrombocytopenia, leukopenia, conjunctivitis, corneal opacity, keratitis, photophobia, eye pain, blepharitis, cataracts, granulocytopenia, epistaxis, pruritus, exfoliative dermatitis, dry skin, maculopapular rash, alopecia.

Generic Availability:

NO

How Supplied:

Caps—60; Oral susp—90mL

Sign Up for Free e-newsletters

Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Genitourinary Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Rare Cancers Regimens
Skin Cancer Regimens Drugs